 Xeris Biopharma Holdings NASDAQ:XERS Inc has announced record third-quarter financial results and subsequently raised its 2022 year-end cash balance guidance. The company reported record net product revenue of 29.6 million, up 17 quarter-over-quarter and 31 year-over-year on a pro forma basis. 